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Hematopoiesis is regulated by crosstalk between
long-term repopulating hematopoietic stem cells
(LT-HSCs) and supporting niche cells in the bone
marrow (BM). Here, we examine the role of CD82/
KAI1 in niche-mediated LT-HSC maintenance. We
found that CD82/KAI1 is expressed predominantly
on LT-HSCs and rarely on other hematopoietic
stem-progenitor cells (HSPCs). In Cd82/mice, LT-
HSCs were selectively lost as they exited from quies-
cence and differentiated. Mechanistically, CD82-
based TGF-b1/Smad3 signaling leads to induction
of CDK inhibitors and cell-cycle inhibition. The CD82
binding partner DARC/CD234 is expressed on mac-
rophages and stabilizes CD82 on LT-HSCs, promot-
ing their quiescence.WhenDARC+BMmacrophages
were ablated, the level of surface CD82 on LT-HSCs
decreased, leading to cell-cycle entry, proliferation,
and differentiation. A similar interaction appears to
be relevant for human HSPCs. Thus, CD82 is a func-
tional surface marker of LT-HSCs that maintains
quiescence through interaction with DARC-express-
ing macrophages in the BM stem cell niche.
INTRODUCTION
Hematopoietic stem cell (HSC) transplantation is the most
widely used regenerative therapy for a variety of life-threatening508 Cell Stem Cell 18, 508–521, April 7, 2016 ª2016 Elsevier Inc.hematologic diseases. An essential factor for successful
transplantation is the fine adjustment of hematopoiesis, deter-
mined by HSCs residing in specialized microenvironments,
termed bone marrow (BM) niches (Morrison and Scadden,
2014). While most HSCs remain dormant in the BM stem cell
niche, they undergo cycles of quiescence and self-renewal
depending on blood cell requirements, which are controlled
by cell-cycle regulators (Tesio and Trumpp, 2011; Zon, 2008).
At the top of the hematopoietic hierarchy, long-term repopulat-
ing hematopoietic stem cells (LT-HSCs) have long-lasting self-
renewal and differentiation capacity, which enables lifelong
production of all hematopoietic lineages, whereas multipotent
progenitor cells (MPPs) only possess transient differentiation
capacity (Doulatov et al., 2012). Although several sets of cell-
surface markers that distinguish HSCs from progenitor cells
(e.g., MPPs) have been reported (Doulatov et al., 2012), the
functional significance of these molecules remains elusive. In
addition to signature molecules on LT-HSCs, other important
factors that may influence the behavior of HSCs, particularly
the quiescence-proliferation decision, include various environ-
mental factors within the BM such as angiopoietin-1, osteo-
pontin, stromal derived factor-1 (SDF-1), thrombopoietin, and
hypoxia inducible factor-1 alpha (HIF-1a) (Kiel and Morrison,
2008; Takubo et al., 2010).
We reported that Cd82, also known as Kangai1 (Kai1),
possesses a hypoxia responsive element in its promoter region
and that its expression is increased in ischemic tissues (Kim
et al., 2010). CD82/KAI1 (CD82 hereafter) belongs to the tetra-
spanin superfamily and was initially identified in studies of
T cell activation (Liu and Zhang, 2006; Miranti, 2009). In partic-
ular, CD82 has attracted attention because low CD82 expres-
sion has been associated with progression of solid tumors and
Figure 1. CD82 Is Expressed Predominantly
on LT-HSCs in the BM Niche
(A) mRNA analysis of the tetraspanin family in BM
LT-HSCs, ST-HSCs, and MPPs (n = 3, hereafter,
n represents the number of biological replicates.)
(B) IF staining of CD82 expressed on BM
LT-HSCs, ST-HSCs, and MPPs. Scale bar, 2 mm
(n = 8).
(C) FACS analysis of the CD82+ portion of BM
SLAM-HSCs and SLAM-MPPs. BM HSPCs were
isolated from the femur and tibia of a single
hindlimb from WT mice (**p < 0.05, n = 3).
(D) (Left) The femoral bone was stained with line-
age cocktail (blue), CD41 (blue), CD48 (blue),
CD82 (green), and CD150 (red). White boxes
indicate CD82+ LT-HSC-enriched areas near the
endosteal surface. Scale bar, 200 mm. (Top right)
The arteriolar niche was stained with lineage
cocktail (blue), CD41 (blue), CD48 (blue), CD82
(white), CD150 (green), and Sca-1 (red). The far-
right panel shows a high-magnification image of
the green boxed area from the left panel. Arrows
indicate CD82+ LT-HSCs in the BM niche. An
asterisk indicates putative MSCs in the arteriolar
niche. Scale bar, 20 mm. (Bottom right) The
endosteal niche was stained with lineage cocktail
(blue), CD41 (blue), CD48 (blue), CD82 (green), and
CD150 (red). The high-magnification image on the
far-right side shows the endosteal niche stained
with lineage cocktail (white), CD41 (white), CD48
(white), CD82 (green), and CD150 (red). Arrows in
both figures indicate CD150+CD82+ LT-HSCs. A
red asterisk indicates the arteriolar niche. Scale
bar, 20 mm.
(E) Distribution of the distances of
LinCD48CD41CD150+CD82+ HSCs from the
endosteal and arteriolar niches in the femoral BM
(60% were within 20mm from both niches) (n = 4
mice, 7 sections, 162 individually validated cells).
All error bars indicate SEM. See also Figure S1.
For (D), the femoral bone image is a composite;
individual images are indicated with gray lines.
Unprocessed individual images are available in
Data S1.because it has been shown to suppress metastasis (Kim
et al., 2005; Miranti, 2009). Moreover, CD82 is ubiquitously ex-
pressed and evolutionally conserved (Liu and Zhang, 2006),
suggesting its functional significance in non-tumor cells as
well.
Duffy antigen receptor for chemokines (DARC)/CD234
(DARC hereafter) is a seven-transmembrane domain protein
expressed on erythrocytes, vascular endothelium, and a sub-
set of epithelial cells (Peiper et al., 1995). Previous reports
have shown that endothelial DARC induces senescence of
CD82+ tumor cells by directly binding to CD82 and is therefore
thought to be essential for CD82-mediated suppression of
cancer metastasis (Bandyopadhyay et al., 2006; Khanna
et al., 2014). However, there are no published data regarding
the surface expression of DARC on niche supporting cells
(NSPs) or its role in the BM niche. In this study, we generated
Cd82/ mice and investigated the role of CD82 and DARC,
along with cells expressing the each molecule, in the BM
stem cell niche.RESULTS
CD82 Is Expressed Predominantly on LT-HSCs
To examine association between the hypoxia-responsive gene
Cd82 and the BM stem cell niche, which is a hypoxic tissue,
we analyzed the expression of CD82 and other tetraspanin
members in highly purified mouse BM hematopoietic stem-pro-
genitor cells (HSPCs; LT-HSCs, short-term repopulating he-
matopoietic stem cells [ST-HSCs], and MPPs) using defined
sets of markers: LT-HSCs (CD34Flt3LineageSca-1+c-Kit+;
LSK) and progeny, including ST-HSCs (CD34+Flt3LSK) and
MPPs (CD34+Flt3+LSK) (Figure S1A).
Interestingly, Cd82 was expressed predominantly in LT-
HSCs, but little was detected in ST-HSCs and MPPs at the
mRNA level. In contrast, other members of the tetraspanin su-
perfamily (Cd9, Cd37, Cd81, and Cd151) were expressed in
every HSPC population (Figure 1A). Similar observations were
made at the protein level by immunofluorescence (IF) (Figures
1B and S1B).Cell Stem Cell 18, 508–521, April 7, 2016 ª2016 Elsevier Inc. 509
Figure 2. LT-HSCs Are Reduced and Exited
from Quiescence in Cd82–/– Mice
(A) Percentage of SLAM-HSCs (CD48CD150+)
among BM LSK of WT and Cd82/ mice
(**p < 0.05, n = 6).
(B) (Left) FACS plot showing LT-HSCs
(CD34Flt3), ST-HSCs (CD34+Flt3), and MPPs
(CD34+Flt3+) in the LSK gate. (Right) Portion of
LT-HSCs among LSK (**p < 0.05, n = 10).
(C) Absolute counts of BM HSPCs in WT or
Cd82/ mice. BM HSPCs were isolated from the
femur and tibia of a single hindlimb from WT mice
(**p < 0.05, n = 4).
(D) Quantification of CFU-GEMM colonies formed
by WT and Cd82/ BM cells (**p < 0.05, n = 3).
(E) Number of LTC-IC colonies formed by WT and
Cd82/ BM cells (**p < 0.05, n = 3).
(F) (Left) Cell cycle status of WT or Cd82/
LT-HSCs. (Right) Quantification of the left plots
(**p < 0.05, n = 5).
(G) (Left) BrdU incorporation into WT and Cd82/
LT-HSCs. (Right) Mean percentage of BrdU-pos-
itive cells (**p < 0.05, n = 3).
(H) mRNA expression of CDK inhibitors (p21, p27,
and p57) in WT and Cd82/ LT-HSCs.
(I) FACS analysis of phosphorylated Rb (pRb) in
LT-HSCs (MFI, mean fluorescence intensity; **p <
0.05, n = 4).
All error bars indicate SEM. See also Figure S2 and
Tables S1 and S2.A recent paper (Oguro et al., 2013) suggested another HSPC
classification based on signaling lymphocytic activation molecule
(SLAM) family markers: (1) SLAM-HSC, or quiescent HSC, with
CD150+CD48CD229CD244LSK and (2) SLAM-MPP with
CD150CD48CD229CD244LSK. Fluorescence-activated cell
sorting (FACS) analysis revealed that 27% of SLAM-HSCs were
CD82 positive, in contrast to merely 4% of SLAM-MPPs (Figures
1C and S1C). Emerging evidence shows that the BM endosteal
and arteriolar niches are indispensable for maintaining HSC
dormancy (Adams and Scadden, 2006; Morrison and Scadden,
2014; Silberstein and Lin, 2013). Consistent with these reports,
whole-mount immunostaining revealed that the majority of CD82+
LT-HSCswere associatedwith the endosteal and arteriolar niches
(Figures 1D and 1E). Taken together, thesedata indicate thatCD82
is a cell surface marker for LT-HSCs in the BM stem cell niche.
The Number of BM LT-HSCs Is Significantly Reduced in
Cd82–/– Mice
To examine whether CD82 affects biological behaviors of
LT-HSCs, we generated the Cd82/ mouse (Figures S2A and510 Cell Stem Cell 18, 508–521, April 7, 2016 ª2016 Elsevier Inc.S2B). We double-confirmed the absence
of CD82 on LT-HSCs and SLAM-HSCs
derived from the BM of Cd82/ mice
(Figure S2C). The percentage of SLAM-
HSCs (CD150+CD48LSK cells) (Kiel
et al., 2005) was significantly lower in
the BM of Cd82/ mice than in wild-
type (WT) counterparts (Figure 2A). Next,
we compared the number of LT-HSCs,
ST-HSCs, and MPPs (Doulatov et al.,2012) in WT and Cd82/ BM. The number of BM LT-HSCs
was significantly lower in Cd82/ mice than WT mice, whereas
the number of ST-HSCs, MPPs, or LSKs was similar (Figures 2B
and 2C). The number of total BMnucleated cells, complete blood
counts, (Figure S2D; Table S1), total and each type of myeloid
progenitor cells (Sca-1c-Kit+ HSPCs in the Lin gate) (common
myeloid progenitor [CMP], granulocyte macrophage [M4] pro-
genitor [GMP], and megakaryocyte erythroid progenitor [MEP])
were similar between the two groups (Figures S2E and S2F).
To further quantify the number of BM HSPCs and long-term
repopulating cells, we performed an in vitro colony-forming unit
(CFU) and long-term culture-initiating cell (LTC-IC) assay (Arai
et al., 2004) using WT or Cd82/ mice. Cd82 deficiency signifi-
cantly decreased the number of CFU-granulocyte, erythroid,
monocyte, and megakaryocyte (CFU-GEMM) colonies as
compared with WT (Figure 2D). Also, the number of LTC-ICs
from the Cd82/ BM was significantly lower than that from WT
BM (Figure 2E). These data suggest that Cd82/ mice show a
selective decrease in LT-HSCs but that the numbers of ST-HSCs
or MPPs are not affected.
Figure 3. CD82 Activates TGF-b1 and TGFbR2 via PKCa and Induces Cell-Cycle Arrest of HSCs
(A) RNA-sequencing of Cd82 K/D and O/E EML cells (n = 2 for Cd82 K/D group, n = 1 for O/E group) (GO: 0045786).
(B) mRNA levels of Cd82, Tgf-b1, and Tgfbr2 in Cd82 K/D and Cd82 O/E EML cells (n = 3).
(C) Western blot analysis of CD82, TGF-b1, TGFbR1, and TGFbR2 in Cd82 K/D and Cd82 O/E EML cells (n = 3).
(D) FACS analysis of TGF-b1, TGFbR1, and TGFbR2 expression on LT-HSCs from WT and Cd82/ mice (**p < 0.05, n = 3)
(E) (Top) Multiplex ELISA of TGF-b1 secretion (n = 3, **p < 0.05). (Bottom) Western blot analysis of TGF-b1 expression in mock and Cd82 O/E EML cells. To
examine the involvement of PKC and Erk in the CD82-induced quiescence pathway, inhibitors for each molecule were used individually in the last two groups.
(F) Western blot analysis of Smad2, Smad3, CDK inhibitors, and Rb in mock,Cd82 K/D, and Cd82O/E EML cells. In theCd82 K/D experimental set, Actin control
(line 6) for the p-Smad3 blot (line 5) is presented right below the p-Smad3 blot. A divider was put between the lanes in the two blots to indicate that we cropped a
lane (Cd82 K/D clone 2) and merged the mock and Cd82 K/D clone 3 lanes (only clone 3 was used in our analyses).
(legend continued on next page)
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Cd82 Deficiency Leads to Loss of LT-HSC Quiescence
To determine why Cd82/ mice had fewer BM LT-HSCs,
we compared the cell-cycle status of BM LT-HSCs of WT and
Cd82/ mice. Cd82 deficiency resulted in prominent cell-cycle
progression, as reflected by a significantly lower percentage of
LT-HSCs in G0 as well as a marked increase in S/G2/M phase
cells (Figures 2F and S2G).
To compare the in vivo proliferation of BM LT-HSCs of WT and
Cd82/ mice, we performed an in vivo bromodeoxyuridine
(BrdU) incorporation assay. The rate of BrdU incorporation in
LT-HSCswas significantly greater inCd82/mice thanWT (Fig-
ure 2G). Notably, we observed a reduction in cyclin dependent
kinase (CDK) inhibitors in Cd82/ LT-HSCs (Figure 2H). These
findings were consistent with increased Rb phosphorylation,
which induces cell-cycle entry (Tesio and Trumpp, 2011;
Zou et al., 2011) (Figure 2I). These data suggest that Cd82/
LT-HSCs are less quiescent and more proliferative than WT
LT-HSCs.
CD82-Activated Signaling PromotesCell-Cycle Arrest in
LT-HSCs
To investigate the mechanisms by which CD82 maintains
LT-HSC quiescence, we performed a series of in vitro gain-
and loss-of-function experiments using EML (erythroid, myeloid,
and lymphocytic: a mouse BM-derived hematopoietic precursor
cell line), which is considered an ideal surrogate for primary
HSPCs and has been widely used in HSC studies (Ye et al.,
2005; Zou et al., 2011). We examined CD82 expression in two
different EML populations: the quiescent LinCD34 fraction
and the actively cycling LinCD34+ population (Zou et al.,
2011). Importantly, we observed prominent expression of
CD82, both at the mRNA and protein levels, in the LinCD34
fraction but little in the LinCD34+ population (Figures S3A and
S3B). To perform gain- or loss-of-function assays, we estab-
lished Cd82 knockdown (K/D) and Cd82 overexpressing (O/E)
stable EML cell lines (Figures S3C and S3D).
Using RNA-sequencing (RNA-seq) analysis, we confirmed that
CDK inhibitors were downregulated in Cd82 K/D EML cells and
upregulated in Cd82 O/E EML cells (Figure 3A). Interestingly,
TGF-b signal components that are upstream regulators of CDK
inhibitors also changed upon Cd82 O/E and K/D (Figures 3A
and S3E).
Cd82 K/D in EML cells lowered TGF-b1 and TGFbR2 expres-
sion, while Cd82 O/E increased their expression; TGFbR1 was
not affected (Figures 3B and 3C). Excitingly, similar results
were observed in FACS analysis of BM LT-HSCs of WT and
Cd82/ mice (Figure 3D). To investigate the functional link
between CD82 and TGF-b1, we evaluated the PKCa and
Erk pathways, which are known to be upstream regulators of
TGF-b1 (Grewal et al., 1999; Shen et al., 2008). CD82 signifi-
cantly induced both expression and secretion of TGF-b1, which
were attenuated only by a PKC inhibitor, but not by an Erk
inhibitor (Figure 3E).(G) Protein levels of CDK inhibitors inmock,Cd82O/E EML cells, andCd82O/E EM
antibody.
(H) Percentage of G0/G1 phase cells among mock or Cd82 O/E Lin
 EML cells.
(I) FACS analysis of the LinCD34 population from mock and Cd82 O/E EML ce
All error bars indicate SEM. See also Figure S3 and Table S2.
512 Cell Stem Cell 18, 508–521, April 7, 2016 ª2016 Elsevier Inc.Since CDK inhibitors were reported as downstream targets
of the TGF-b/Smad3 pathway (Li et al., 1995; Scandura et al.,
2004), we examined the activation of Smad2/3. Cd82 O/E
induced phosphorylation of Smad3, increased CDK inhibitors,
and inhibited Rb phosphorylation, whereas the Cd82 K/D gave
opposite results (Figure 3F). Induction of CDK inhibitors by
CD82 was blocked by a TGFbR inhibitor and TGF-b1 neutraliza-
tion (Figure 3G). Interestingly, Cd82 O/E repressed cell-cycle
progression from theG0/G1 to S phase (Figure 3H) and increased
the proportion of LinCD34 quiescent EML (qEML) cells
(Figure 3I).
Taken together, our results indicate that CD82 represses the
cell cycle and maintains quiescence of LT-HSCs through the
activation of TGF-b1/Smad3 signaling via PKCa, leading to in-
duction of CDK inhibitors and cell-cycle arrest.
CD82 Regulates the Cell-Cycle Status and Long-Term
Repopulation Capacity of LT-HSCs
We compared the BM recovery rate of WT and Cd82/ mice
after irradiation. Cd82/ BM exhibited a greater ablation (Fig-
ure S4A), presumably because Cd82 deficiency led to increased
cell proliferation and resultant susceptibility to irradiation. To
investigate whether CD82 affects the long-term repopulating
capacity of HSCs, we performed a competitive BM transplanta-
tion (BMT) in which sublethally irradiated recipient mice (CD45.1)
were transplanted with HSPC-enriched Lin BM cells (CD45.2)
from WT or Cd82/ mice plus competitor cells (CD45.1) (Fig-
ure 4A). On week 16 post-BMT, we assessed the chimerism of
donor-derived cells (CD45.2) in the recipient mice (CD45.1).
The repopulating ability of Cd82/ HSPCs was inferior to that
of WT cells (Figure 4A). In the secondary BMT, the BM of mice
that received Cd82/ HSPCs had fewer LSKs and LT-HSCs
than WT BM (Figure 4B). The percentage and number of
LT-HSCs in G0 was significantly greater in recipients receiving
WT HSPCs (Figures 4C and 4D).
Notably, as much as 67% of Cd82/ LT-HSCs were in G1
phase (Figure 4C), which was quite different pattern than that
shown in Figure 2F (in which only 16% were in G1 and 54% in
S/G2/M phase). Figure 2F shows an analysis of Cd82
/
LT-HSCs obtained from Cd82/ whole-body-knockout mice,
whereas Figure 4C shows the cell-cycle status of Cd82/
donor-derived LT-HSCs harvested from WT recipient mice.
Thus, we speculated such differences might be attributable
to different CD82 expression of NSPs. Among BM niche com-
ponents (osteoblasts [OBs], endothelial cells [ECs], and mesen-
chymal stromal cells [MSCs]), MSCs exhibited much greater
CD82 expression versus ECs and OBs (Figures S4B–S4D).
To study the influence of MSCs on cell-cycle progression in
LT-HSCs, we generated a Cd82 K/D mesenchymal stromal cell
line (C3H/10T1/2, hereafter 10T1/2) (Konieczny and Emerson,
1984) and co-cultured LT-HSCs isolated from Cd82/ mice
with mock or Cd82 K/D 10T1/2 cells. LT-HSCs co-cultured
with Cd82 K/D MSCs exhibited higher S/G2/M, lower G1, andL cells treatedwith TGFbR inhibitor, SB431542 (50 mM), or TGF-b1 neutralizing
lls.
Figure 4. Role of CD82 in Post-transplant
BM Repopulation
(A) (Top) Schematic representation of the
competitive BMT. Donor (CD45.2)-derived Lin
BM cells (WT or Cd82/) and competitor cells
(CD45.1) were transplanted in sublethally irradi-
ated recipient mice (CD45.1). (Bottom) Mean
percentage of donor- or recipient-derived cells in
the peripheral blood 16 weeks after competitive
BMT (**p < 0.05, n = 3).
(B) The repopulating capacity of WT and Cd82/
cells was determined via quantification of the ab-
solute numbers of donor-derived LSK (Left) and
LT-HSCs (right) from recipient BM after primary or
secondary BMT. All cell counts in Figure 4 were
conducted with BM cells from the femur and
tibia of a single hindlimb fromWTmice. (**p < 0.05,
n = 3).
(C) Cell-cycle status of donor-derived LT-HSCs
after secondary BMT (n = 3).
(D) Absolute number of donor-derived LT-HSCs
in G0 after primary or secondary BMT (**p < 0.05,
n = 3).
(E) The percentage of CD11b+ myeloid cells
(myeloid), CD3+ T cells (T), or CD45R/B220+ B
cells (B) that were differentiated from donor-
derived HSPCs after primary or secondary BMT
(**p < 0.05, n = 3).
All error bars indicate SEM. See also Figure S4.similar G0 populations than LT-HSCs cultured with mock MSCs
(Figure S4E), suggesting that CD82 on MSCs is important for
G1 check of LT-HSCs. Cd82 K/D reduced Tgf-b1 expression in
10T1/2 cells (Figure S4E), which may be the mechanism by
which MSCs downregulate the G1-to-S/G2/M transition.
Another interesting observation from the serial BMT was that
HSCs from Cd82/ mice showed preferential differentiation
toward a myeloid lineage (Figure 4E). These tendencies were
also observed in fresh BM from WT and Cd82/ mice (Fig-
ure S4F) and were corroborated by RNA-seq analysis of EML
cells in which Cd82 K/D decreased gene expression of negative
regulators for myeloid differentiation (Figure S4F). We specu-
lated such myeloid bias might be associated with CD82 expres-
sion on myeloid progenitors. However, myeloid progenitors dis-
played low CD82 expression: CMP (6.8% ± 2.3%), GMP (2.3% ±
1.4%), and MEP (1.2% ± 0.5%) (Figure S4B).
Collectively, these data indicate that CD82 plays a signifi-
cant role in maintaining the long-term repopulating capacity of
HSCs and that Cd82-deficient HSCs show myeloid-biased
differentiation.Cell Stem Cell 18, 508–The CD82 Binding Partner DARC Is
Highly Expressed on BM Niche
Macrophages
The above findings led us to investigate
the molecule that interacts with CD82 to
activate the CD82-PKCa pathway in LT-
HSCs. A previous report demonstrated
that CD82 binds to DARC (Bandyopad-
hyay et al., 2006). Also, cells such as
ECs, MSCs, OBs, and M4 have all been
shown to support the BM stem cell niche(Kiel and Morrison, 2008; Morrison and Scadden, 2014). There-
fore, we examined whether and if so which of these cells express
DARC. Interestingly, 38.4%± 1.2%of BMM4 (CD11b+Gr1lowF4/
80+SSClow) and as many as 64% ± 5% of F4/80+ BM M4 were
DARChigh (Figures 5A and S5B). Other niche-supporting cells
(OBs, ECs, and MSCs) rarely expressed DARC (Figures S5A
and S5C). F4/80+DARC+ M4 was detected both in the arteriolar
and endosteal niches (Figure 5B). Furthermore, 10% of DARC+
M4 expressed a-smooth muscle actin (a-SMA) and cyclooxyge-
nase-2 (COX-2), which implies a functional overlap with a subset
of M4 that was recently been described to promote LT-HSC
quiescence (Ludin et al., 2012) (Figure S5D). We also detected
DARC+aSMA+ M4 in the BM endosteal niche by IF analysis (Fig-
ure S5E). Therefore, we focused on investigating how DARC-
expressing M4 function through the molecule.
Next, we examined whether DARC on M4 directly interacts
with CD82 on LT-HSCs in the BM niche. IF staining of mouse
bone revealed that DARC+ M4 are in direct contact with
CD150+CD82+ quiescent LT-HSCs in the endosteal and arteri-
olar niches (Figure 5C). Since Tie2 has also been identified as521, April 7, 2016 ª2016 Elsevier Inc. 513
a marker for LT-HSCs (Arai et al., 2004), we employed Tie2-GFP
mice. As expected, DARCwas shown to have direct contact with
CD82 on green LT-HSCs in the BMof Tie2-GFPmice (Figure 5C).
In in vitro co-culture experiments, DARC on M4 was adjacent to
CD82 on HSPCs (Figure 5D) and CD82+ HSPCs that were main-
tained with M4 were less proliferative (Ki-67 negative) than
mono-cultured CD82+ HSPCs (Figure S5F). Direct interaction
of CD82/DARC was also confirmed by co-immunoprecipitation
of EML cell lysates (Figure 5E). Importantly, co-culture of pri-
marily isolated HSPCs and M4 induced G0 arrest of LT-HSCs
(Figure 5F).
In order to see whether DARC is involved in the anti-prolifera-
tive effect of M4, we analyzed the cell-cycle status of primary
LT-HSCs after co-culture either with primary DARC+ or with
DARC M4. As expected, while DARC+ M4/HSPC co-culture
successfully maintained dormancy of LT-HSCs, co-culture with
DARCM4 did not (Figure S5G). The number of CD82+ LT-HSCs
that were cultured with DARC+ M4 was significantly higher than
those cultured with DARC M4 (Figure S5H), given that the
former were maintained as LT-HSCs while the latter underwent
proliferation.
Next, we performed an in vitro mechanistic analysis using pri-
mary cells that were genetically manipulated with exogenous
small hairpin RNA (shRNA) against Tgf-b1 or Smad3 (Figure S5I).
HSPC/M4 co-culture resulted in a 2-fold higher G0 population in
LT-HSCs versus HSPC mono-culture. Also, as expected, K/D of
Tgf-b1 or Smad3 in LT-HSCs led to a decreased G0 population
even in the presence of DARC+ M4. Additionally, HSPC/M4
co-culture led to lower levels of Rb phosphorylation (i.e., cell-
cycle downregulation) in mock-transduced LT-HSCs, but this
response was compensated for by Tgf-b1 or Smad3 K/D in
LT-HSCs (Figure 5G). These data indicate that DARC on M4
triggers quiescence signaling in LT-HSCs via surface CD82 of
LT-HSCs.
In contrast to broad expression of DARC on human ECs (Ban-
dyopadhyay et al., 2006), only0–1% of the two types of mouse
BM ECs were positive for DARC. Moreover, regardless of origi-
nating tissue, ECs very weakly expressed DARC (Figures S5A,
S5J, and S5K). To determine the possible influence of endo-
thelial DARC on cell-cycle status of LT-HSCs, we performed
gain-of-function assays using two different endothelial cell lines
(C166, MS-1) that were genetically manipulated to overexpress
DARC (Figure S5L). Interestingly, there was virtually no differ-
ence in the cell-cycle status of LT-HSCs co-cultured either
with mock or Darc O/E C166 cell lines (expressing high basal
level of DARC), while the percent of LT-HSCs in G0 that were
co-cultured with Darc O/E MS-1 was significantly higher than
those cultured with mock MS-1 cell line (expressing low basal
level of DARC) (Figures S5L and S5M).
Thus, DARC, which is highly expressed on M4 but rarely on
ECs, regulates LT-HSC quiescence through direct contact with
CD82 on LT-HSCs in the BM niche.
Ablation of DARC-Expressing Macrophages Reduces
Surface CD82 Expression on LT-HSCs
To examine the role of CD82 and DARC in maintaining LT-HSC
quiescence and reconstituting the BM after ablative intervention,
we monitored sequential changes in CD82+ LT-HSCs and prolif-
erating blood cells after a single-dose of 5-FU. Since 5-FU in-514 Cell Stem Cell 18, 508–521, April 7, 2016 ª2016 Elsevier Inc.duces apoptosis primarily in actively cycling progenitors and
mature blood cells (Brenet et al., 2013; Winkler et al., 2012),
the number of total BM cells rapidly decreased (Figure 6A),
necessitating a new cell supply from quiescent LT-HSCs that
survived the 5-FU treatment. In response to a reduction in BM
cells, the percentage of CD82+ cells in the CD34LSK population
rose until day 2, plummeted to reach a nadir on day 5, and re-
turned to a normal level 2 weeks after 5-FU treatment (Figures
6B and S6A). Reduction in CD82 expression on LT-HSCs on day
5 was accompanied by the start of cell proliferation (Figures 6C
and S6B).
In the BMmyeloablation model, overall DARC expression was
maintained till day 2 post 5-FU injection, dropped on day 5, and
then recovered afterward (Figure S6C). The percent of DARC+
M4 elevated during the first 2 days after 5-FU challenge,
decreased until 5-FU treatment day 5, and then gradually recov-
ered (Figures 6D, 6E, and S6D). Importantly, according to our
FACS analysis, M4 is the only nucleated cell type that expresses
DARC in the BM (Figure S5A). These data indicate that the recov-
ery of DARC expression after BM ablation is due to an increase in
DARC+ M4.
The fact that CD82 and DARC directly contact each other,
and that CD82+ LT-HSCs and DARC+ M4 exhibit a similar
pattern of rise and fall after 5-FU treatment (Figures 6B and
6D), led us to hypothesize that depletion of DARC+ M4 weakens
CD82/DARC interactions, resulting in decreased CD82 levels on
LT-HSCs. We tracked time-dependent changes in LT-HSC/M4
interactions following 5-FU treatment. Bones that were
harvested on day 5 post 5-FU injection showed only a few
LT-HSCs and DARC+ M4 (Figure S6E). Importantly, neither
LT-HSCs nor co-localization of LT-HSCs and DARC+ M4
was observed. On day 10 post-5-FU injection, bones clearly
showed BM reconstitution. Interestingly, near the endosteal
surface, several DARC+ cells were clustered around LT-HSCs
(Figure S6E).
Next, we investigated the effect of M4 depletion by clodronate
(Petersen et al., 2014) on CD82+ LT-HSCs. Clodronate effec-
tively removed total and DARC+ M4 (Figures S6F and S6G),
leading to a marked reduction in the number of total and
CD82+ LT-HSCs (Figures 6F and S6H).
Next, we mimicked in vivo BM ablation by co-culturing qEML
cells with various numbers of Raw 264.7 cells (mouse macro-
phage cell line). Of interest, CD82 expression was maintained
on qEML co-cultured with Raw 264.7 cells, and CD82 levels on
qEML were positively correlated with the number of co-cultured
Raw 264.7 cells (Figure 6G).
To explore the direct influence of macrophagic DARC to
regulate CD82 expression on HSC, we established a Darc K/D
Raw 264.7 cell line (Figure S6I). CD82 on qEML cells significantly
decreased when co-cultured with Darc K/D Raw 264.7 cells
(Figure 6H).
We further investigated themechanism through which CD82 is
decreased. It has been reported that CD82 expression level is
modulated by ubiquitination (Tsai et al., 2007) and endocytosis
(Xu et al., 2009). Thus, we speculated that after losing direct con-
tact with DARC on a macrophage, CD82 on LT-HSCs might first
be ubiquitinated and then endocytosed. We detected CD82
ubiquitination when qEML cells were cultured in proliferation
conditions (Figure 6I). Also, CD82+ qEML cells maintained under
(legend on next page)
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proliferation conditions for 2 days exhibited markedly reduced
CD82 expression. Notably, CD82 expression on qEML cells
was preserved by treatment with the proteasome inhibitor MG-
132, similar to DARC+ M4 co-culture (Figure S6J).
Next, we performed an endocytosis assay on co-cultured
qEML and Raw 264.7 cells. When co-cultured with DARC-posi-
tive ‘‘mock’’ M4, qEML showed no sign of CD82 endocytosis.
However, when qEML cells were cultured alone or with Darc
K/D M4, CD82 endocytosis was significantly increased, which
was reversed by treatment with recombinant human DARC
(rhDARC) or MG-132 (Figures 6J and S6K).
For further validation of our hypothesis, we measured surface
CD82 expression of qEML by FACS without removing surface-
bound antibodies. As expected, the surface level of CD82
decreased when mono-cultured in proliferation conditions but
was maintained when co-cultured with M4 (Figure S6L). Taken
together, our IF and FACS data indicate that qEMLmono-culture
in proliferation conditions induced CD82 endocytosis and
concomitant reduction of surface CD82 expression, which can
be blocked by either M4 DARC or rhDARC. Importantly, while
CD82 protein levels fluctuated in reaction to various experi-
mental conditions, CD82 displayed no significant changes at
the mRNA level (Figure S6M).
Although surface CD82 levels had been lowered by ubiquitina-
tion-endocytosis in qEMLmono-culture, subsequentM4 co-cul-
ture or rhDARC treatment rapidly restored CD82 expression. In
contrast, sustained mono-culture or Darc K/D M4 co-culture
failed to restore surface CD82 expression (Figures 6K and S6N).
Moreover, as in primary cultures, maintaining qEML cells with
Darc K/D Raw 264.7 cells resulted in a much lower percentage
of qEML cells in G0. Interestingly, pre-treating qEML cells with
rhDARC before co-culture successfully maintained qEML cell
dormancy (Figure S6O). Furthermore, rhDARC activated PKCa
phosphorylation via interaction with CD82 on qEML cells
(Figure S6P).
Thus, 5-FU abolishes DARC-expressing BM M4, leading
to disruption of the interaction between DARC on M4 and
CD82 on LT-HSCs. This results in ubiquitination, endocytosis,
and degradation of CD82 in LT-HSCs. Loss of CD82 causes
LT-HSCs to switch to the proliferation/differentiation stage in
order to regenerate the BM. After BM regeneration, increased
DARC-expressing M4 recover CD82 expression on LT-HSCs,
returning to homeostasis.Figure 5. M4 Express DARC, a Counter-molecule of CD82, and Are Ph
(A) Representative FACS plot showing surface expression of DARC on BM M4 (
(B) (Left) DARC+F4/80+ M4 in the BM arteriolar niche (Sca-1+). (Center) High
F4/80+DARC+ M4 in the arteriolar niche. (Right) Arrows indicate DARC+ M4 in th
(C) (Top) CD82+CD150+ LT-HSCs andDARC+M4 located adjacent to each other i
LT-HSCs and DARC+ M4 located adjacent to each other in the BM of the Tie2-G
(D) (Top) Schematic representation of the experiment. Lin cells, MACS-sorted fr
were also MACS-sorted from the BM. (Bottom) IF analysis was performed to confi
CD82+Lin cells, and the red cell is an F4/80+DARC+ macrophage. Scale bar, 10
(E) CD82/DARC interaction in EML cells was confirmed by co-immunoprecipitati
(F) (Left) Cell-cycle status of the primary LT-HSC gate, which was either mono-cult
the same set of experiments (**p < 0.05, n = 3).
(G) (Top) Schematic representation of the experiment. (Center) Cell-cycle statu
shSmad3 lentivirus. Mock-transduced HSPCs were either mono-cultured or cultu
were cultured with primary F4/80+ M4. (Bottom) Phosphorylated Rb expression
All error bars indicate SEM. See also Figure S5.
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LT-HSCs
TodeterminewhetherCD82 is selectively expressedbyandmain-
tainsquiescenceof primitiveHSCs (hereafterHSCs) in humansas
well as mice, we examined HSCs from human umbilical cord
blood (hUCB). We evaluated CD82 expression on human HSCs
(LinCD34+CD38 and LinCD34CD38CD93highCD45RA)
(Anjos-Afonso et al., 2013; Laurenti et al., 2015). CD82 was ex-
pressed on 98% ± 0.5% of LinCD34+CD38 cells, a human
HSC population with high reconstituting potential (Figure S7A),
and on one-quarter of LinCD34CD38CD93highCD45RA
HSCs, another quiescent HSC population with severe combined
immunodeficiency (SCID)-repopulating capacity at the top of
the human hematopoietic hierarchy (Anjos-Afonso et al., 2013)
(Figure 7A).
Most CD82+ HSCswere in G0 phase, while only 20%of CD82

HSCs were in G0 (Figure 7B). Additionally, the majority of CD82

HSCs were positive for Ki-67, a proliferation marker, whereas
CD82+ HSCs were primarily Ki-67 negative (Figure 7C). Also,
the CD82+ HSC fraction exhibited upregulation of CDK inhibitors
(Figure 7C).
To confirm that PKCa phosphorylation is upstream of the CDK
inhibitors, CD82+ and CD82 HSC fractions were treated with
rhDARC. PKCa signaling was activated in rhDARC-treated
CD82+ HSCs, but not in CD82 HSCs (Figure 7D). Furthermore,
rhDARC blocked G0 exit of CD82
+ HSCs (Figure 7E). As in mice,
human monocytes/M4 exhibited the highest DARC expression
level among hUCB component cells. T cells, B cells, Lin cells,
and ECs exhibited very weak DARC expression (Figure S7B).
To demonstrate DARC functionality in humans, HSPCs
(LinDARC) were subjected to proliferation conditions and
cultured with or without DARC+ monocyte/M4 or rhDARC.
HSCs co-cultured with DARC+ monocyte/M4 or treated with
rhDARC displayed marked upregulation of CD82 (Figure 7F).
In conclusion, CD82 is selectively expressed on primitive
HSCs in humans as well; in addition, the majority of CD82+
HSCs are quiescent, which is maintained by DARC-expressing
monocytes/M4.
DISCUSSION
Our findings, summarized as follows, provide a putative
model for quiescence/proliferation cycle of LT-HSCs duringysically Associated with CD82+ LT-HSCs
CD11b+Gr1lowF4/80+SSClow).
-magnification images of the boxed area in the left figure. Arrows indicate
e BM endosteal niche. Scale bar, 5 mm.
n the BM endosteal and arteriolar niche. Scale bar, 10 mm. (Bottom) CD82+Tie2+
FP mouse. Scale bar, 5 mm.
om the mouse BM, were CFSE-stained and co-cultured with F4/80+ M4 which
rm CD82/DARC interaction. Green- and white-labeled cells are CFSE-stained
mm.
on (co-IP).
ured or cultured with primary F4/80+M4. (Right) Absolute counts of LT-HSCs in
s of primary LT-HSCs that were transduced either with mock, shTgf-b1 or
red with primary F4/80+ M4, and shTgf-b1- and shSmad3-transduced HSPCs
of LT-HSCs was assessed in the same set of experiment.
Figure 6. In the BM Niche, DARC-Express-
ing M4 Regulate CD82 on LT-HSCs during
Homeostasis/Regeneration
(A) Number of total BM cells at different time points
after 5-FU injection (n = 6). x axes of Figures 6A–6E
represent days after 5-FU injection (day 0). All cell
counts in Figure 6 were conducted with BM cells
from the femur and tibia of a single hindlimb from
WT mice.
(B) Sequential changes in percentage of CD82+
cells in BM LT-HSCs (CD34LSK) after 5-FU in-
jection (n = 3).
(C) Sequential changes in percentage of prolifer-
ating cells (Ki-67+) in the BM (n = 5).
(D) Sequential changes in percentage of DARChigh
cells in BMM4 (CD11b+Gr1lowF4/80+SSClow) after
5-FU injection (n = 3).
(E) Sequential changes in the number of DARChigh
(red) and total BM M4 (blue) after 5-FU injection
(n = 3). Total M4 includes the DARChigh population.
Rapid decrease in DARC M4 in early days after
5-FU treatment led to an increased relative pro-
portion of DARC+ M4 in the BM.
(F) The number of CD82+ cells in the BM LT-HSC
population (CD34Flt3LSK) on the day following
treatment with control or clodronate liposomes
(**p < 0.05, n = 3).
(G) Changes in CD82+ positivity of qEML
cells depending on the density of co-cultured M4
(n = 3).
(H) Percentage of CD82+ cells in qEML cells that
were cultured either with mock or Darc K/D Raw
264.7 cells (**p < 0.05, n = 3).
(I) MACS-sorted qEML cells were subjected to
proliferation conditions and their protein expres-
sion was analyzed by co-IP (CD82) and immuno-
blot (ubiquitin).
(J) (Top) To analyze CD82 internalization, qEML
cells were incubated with biotin-conjugated
CD82 antibody and then either mono-cultured (I),
cultured with mock Raw 264.7 cells (II), cultured
with Darc K/D Raw 264.7 cells (III) or cultured with
Darc K/D Raw 264.7 cells in the presence of
rhDARC (IV) or MG-132 (V). After removal of un-
internalized antibodies with acid wash, cells were
fixed, permeabilized, stained with a fluorescent
streptavidin conjugate, and observed using confocal microscopy. (Bottom) CD82 endocytosis was quantified in terms of the number of vesicles per cell
(**p < 0.05, n = 5).
(K) Percentage of CD82+ cells (in the c-Kit+LinCD34 gate) was measured (left) after 1-day mono-culture of qEML cells. (Right) Later, the cells were further
subjected tomono-culture (1), co-culture withmockM4 (2), co-culture withDarcK/DM4 (3), or co-culture withDarcK/DM4 after 1-hr pretreatment with rhDARC.
Two days later, surface CD82 levels were estimated by FACS.
All error bars indicate SEM. See also Figure S6.the post-ablation recovery process. (1) During homeostasis,
CD82 maintains the dormancy of LT-HSCs through interac-
tion with DARC on M4. (2) Under BM ablation, CD82+ LT-
HSCs and DARC+ M4 initially resist the ablative stimuli.
Then, the DARC+ M4 population decreases, causing LT-
HSCs to lose surface CD82. (3) CD82 loss causes quiescent
LT-HSCs to enter the cell cycle and undergo differentiation,
regenerating the BM. (4) Newly generated DARC-expressing
M4 brings reduced CD82 expression on LT-HSCs to normal
levels and induces cell-cycle exit in LT-HSCs, returning to
homeostasis. We also demonstrated CD82/DARC interaction
in humans. These findings demonstrate that CD82 is a func-
tional surface marker of LT-HSCs and that the moleculemaintains LT-HSC quiescence by interactions with DARC-ex-
pressing M4.
Until now, several defined sets of surface markers have been
used to define higher level BM stem cells, such as LT-HSCs and
HSC-1, or quiescent HSCs (CD150+CD48CD229CD244LSK)
based on SLAM family markers (Adolfsson et al., 2005; Kiel et al.,
2005; Oguro et al., 2013). However, the functions of these
markers remain unknown. In this paper, we report that CD82 is
a marker for LT-HSCs and has a physiological function in main-
taining HSC quiescence, which determines BM reconstituting
capability. Our data show that at the mRNA level, CD82 is ex-
pressed predominantly on LT-HSCs while little is detected on
ST-HSCs andMPPs. Similar results were observed at the proteinCell Stem Cell 18, 508–521, April 7, 2016 ª2016 Elsevier Inc. 517
Figure 7. Quiescence of Human CD82+
Primitive HSCs Is Maintained by rhDARC
and DARC-Expressing M4
(A) (Left) CD82 expression of hUCB-derived primi-
tive HSCs (HSCs, LinCD34CD38CD93high
CD45RA). (Right) Percentage of CD82 and
CD82+ populations in HSCs (**p < 0.05, n = 4).
(B) (Left) Cell-cycle status of CD82 and CD82+
HSCs. (Right) Quantification of the left plot (**p <
0.05, n = 3).
(C) (Top) Schematic figure showing purification of
HSCs. MACS-sorted LinCD235a hUCB cells
were further sorted into two groups (CD34
CD38CD93highCD45RACD82 and CD34
CD38CD93highCD45RACD82+ populations) by
FACS. (Bottom left) Representative IF images
showing Ki-67 expression in CD82 and CD82+
HSCs. Quantification of the IF analysis. Scale bar,
2 mm. (Bottom right) mRNA expression of CD82
and CDK inhibitors (p21, p27, and p57) in CD82
and CD82+ HSCs.
(D) CD82+ and CD82 HSCs were separated by
FACS, and rhDARC-induced PKCa phosphoryla-
tion (pPKCa) was observed by confocal imaging.
Scale bar, 2 mm.
(E) (Left) FACS analysis revealed rhDARC blocked
G0 exit of HSCs. (Right) Quantification of the left
plot (**p < 0.05, n = 4).
(F) (Top) Schematic figure of the experiment.
LinDARC HSPCs and monocytes were isolated
from hUCB. LinDARC cells were then cultured
alone, co-cultured with monocytes, or treated
with rhDARC. (Bottom) CD82 surface expres-
sion of the three groups of HSCs (gated on Lin
CD34CD38CD93high) was estimated with FACS.
All error bars indicate SEM. See also Figure S7
and Table S3.level, with larger differences in expression between LT-HSCs
and HSPC populations. The significance of this study is that
CD82 not only serves as amarker for LT-HSCs but also functions
to maintain LT-HSC quiescence. In this regard, it is interesting
that the percentage of CD82+ cells in the LT-HSC population
(CD34LSK) increased during the first 2 days after 5-FU chal-
lenge (Figure 6B). This implies that CD82+ LT-HSCs are resistant
to myeloablation, which might be explained by a comparatively
lower proliferation rate (i.e., quiescence) of CD82+ cells.
Our results regarding the mRNA expression pattern of Cd82
in HSPCs are consistent with those from established data-
bases (http://www.immgen.org and http://gexc.stanford.edu).
Although the former shows a different result when the SLAM
definition (instead of the Flt3, CD34, and LSK marker combina-
tion) is applied, Cd82 mRNA levels do not necessarily correlate
with protein levels. In this study, we showed that there was a
significantly higher expression of CD82 in LT-HSC than on either
ST-HSC or MPP both at the mRNA and protein levels. Further-
more, considering that CD82 is primarily regulated at the protein518 Cell Stem Cell 18, 508–521, April 7, 2016 ª2016 Elsevier Inc.level in response to external stimuli (e.g.,
M4 co-culture, rhDARC treatment), the
analysis of protein levels seems to be a
more reliable and accurate indicator of
functional expression.Compared to their WT counterparts, Cd82/ mice had fewer
LT-HSCs (Figures 2A–2C) and more myeloid cells (Figure S4F),
which implies that Cd82/ LT-HSCs might have undergone
myeloid-biased differentiation. This was also demonstrated in
our in vivo transplantation model which showed that HSPCs
from Cd82/ mice had reduced long-term repopulating capac-
ity and showed myeloid-biased differentiation (Figure 4E), a
unique characteristics of aging HSCs (Rossi et al., 2005, 2008).
Therefore, we speculate that CD82 regulates the repopulating
capacity, aging and lymphoid-myeloid lineage commitment of
HSCs.
Because we used whole-body Cd82 knockout mice, we
cannot exclude the possibility that Cd82 deletion of NSPs
may directly or indirectly influence CD82 surface expression
or LT-HSC functionality. A series of cell-cycle analyses provide
an explanation for CD82 involvement in the LT-HSC and NSP
influence on cell-cycle entry and progression of LT-HSCs: after
the absence of CD82 on quiescent LT-HSCs allows cells to
exit from G0 and enter G1 phase, Cd82 deficiency in LepR
+
MSCs accelerates the G1-to-S/G2/M transition in LT-HSCs
(Figure S7C).
Recent studies have also investigatedwhethermonocytes/M4
regulate the quiescence or mobilization of HSPCs in a paracrine
manner using BM NSPs (Chow et al., 2011; Ehninger and
Trumpp, 2011). Importantly, COX-2-induced production in and
secretion ofPGE2 froma rareaSMA
+BMM4population prevents
ROS production in LT-HSCs, thereby maintaining undifferenti-
ated LT-HSCs (Ludin et al., 2012). We found that DARC+M4 dis-
played much higher aSMA and COX-2 expression than the
DARC fraction (Figures S5D and S5E). Given that after M4
loseCOX-2 activity, they no longermaintain LT-HSCquiescence,
there is a possibility that crosstalk exists between the DARC/
CD82 axis and COX-2-mediated PGE2 generation. Our study
adds to the findings of Ludin et al. and highlights the importance
of M4 as a HSC niche component governing HSC quiescence.
Most interestingly, HSC-derived megakaryocytes also directly
regulate quiescence of HSCs in the BM niche (Bruns et al., 2014;
Zhao et al., 2014).We speculate that LT-HSCs themselves differ-
entiate into DARC+M4 to regenerate the HSC niche that induces
and maintains LT-HSC quiescence. Further studies that employ
transgenic mice allowing specific labeling and tracing of DARC
will provide more conclusive explanations of the late-stage BM
regeneration process.
Generally, the lysosomal degradation axis consists of two
branched pathways: endosomes (endolysosomal degradation)
or autophagosomes (autophagy). p62 (SQSTM1) is a well-known
ubiquitin-binding protein, which is required for the selective
autophagy process (Moscat and Diaz-Meco, 2009). Moreover,
p62 in osteoblasts can inhibit NF-kB signaling in an endosteal
macrophage-dependent manner, which is important for reten-
tion of ST-HSCs and hematopoietic progenitors (HPs) (Chang
et al., 2014). However, Chang et al. focused only on ST-HSCs
and HPs via indirect effects of M4. Here, we report that
DARC+ M4 directly regulate LT-HSC retention. DARC+ M4, but
not DARC M4, maintained LT-HSC quiescence by physically
binding CD82 on the surface of LT-HSCs, thereby preventing
its degradation. Further study is required to elucidate whether
and how p62 is involved in CD82 degradation, as well as
DARC downstream signaling as part of a M4-specific mecha-
nism regulating LT-HSC egression.
Our data show little surface expression of DARC on NSPs
(e.g., ECs, MSCs and osteoblasts) (Figures S5A and S5C). While
human ECs are known to express DARC (Bandyopadhyay et al.,
2006), our flow cytometry data clearly show that murine ECs
derived from various organs as well as the BM only weakly
express DARC (Figures S5A, S5J, and S5K). While endothelial
DARCwas also shown to regulate LT-HSC quiescence, potential
endothelial influence on LT-HSC cell-cycle status through the
CD82/DARC axis is unlikely considering the very low level of
DARC expression on BM ECs, which highlights the significance
of DARC+ M4 in maintaining HSC quiescence.
In humans as well, rhDARC maintained CD82 expression on
HSCs and blocked G0 exit of HSCs (Figures 7E and 7F). The
rhDARC protein we used in this study is embedded in the lipo-
somal membrane, which allows the molecule to fold into and
maintain its native 3D structure, thereby exerting its expected
functions. Previous reports have shown that DARC also binds
both C-C and C-X-C chemokines (Khanna et al., 2014). Thus,the identification of the paracrine factors that mediate the para-
crine interaction between DARC+ M4 and CD82+ HSCs is an
important issue for further studies.
Ex vivo expansion of and gene therapy using HSCs are attrac-
tive therapeutic strategies for many hematologic diseases in the
clinic. Generally, ex vivo expanded HSPCs are actively cycling
and have impaired capacity for homing and engraftment
compared with freshly isolated HSPCs. While transplantation
of ex vivo expanded HSCs in mice showed successful long-
term repopulation in many studies, the results were not repro-
duced in a primate study (Watts et al., 2011).
In human, the majority of LinCD34+CD38 and Lin
CD34CD38CD93high HSCs (CD34+ andCD34HSCs, respec-
tively) are quiescent and both express significant CD82 levels,
which suggests that CD82 may play a role in maintaining quies-
cence of CD34+ HSCs as well. It is not clear if CD34+ or CD34
HSCs are more primitive (Engelhardt et al., 2002). Therefore,
determining a hierarchical relationship between CD34+CD82+
and CD34CD82+ cells by estimating the long-term repopulating
capacity of the two populations will help resolve this controversy.
Also, considering that macrophagic DARC or rhDARC increases
surface CD82 expression and induces cell-cycle exit in human
CD34 HSCs, rhDARC treatment may secure the HSC (either
CD34+ or CD34) pool size after BM regeneration by upregulat-
ing/restoring surface levels of CD82 on HSCs, forcing them back
to dormancy.
One possible therapeutic scheme would be to incubate HSCs
with soluble DARC at a specific time point during ex vivo expan-
sion for BMT. Further study is necessary in order to determine
the effect of soluble DARC protein on the repopulation capacity
of HSCs. Identifying other factors regulating CD82 expression in
HSCs and elucidating DARC downstream will facilitate the
development and optimization of a treatment protocol capable
of exploiting the CD82/DARC axis.EXPERIMENTAL PROCEDURES
Generation of Cd82–/– Mice
To create a conditional targeting vector in which exon 5 and exon 6 of the Cd82
genewere flanked by loxP sites, the genomic region fromexon 4 to exon 7 used
to construct the targeting vector was first subcloned from a BAC clone (Source
BioScience) into a pBluescript phagemid system. The FRT-flanked neomycin
cassette containing a loxP sequence was inserted at the 30 end of exon 6, and
a single loxP sitewas insertedat the50 of exon5. 20mg targeting vectorwas line-
arized using NotI restriction enzyme and transfected into E14Tg2A ES cells
(BayGenomics) by electroporation. After neomycin selection, surviving clones
were expanded to identify recombinant embryonic stem cell (ESC) clones by
Southern blot analysis. Following EcoRI digestion, the bands representing WT
and targeted alleles are 11.5 kb and 7.7 kb, respectively. The DNA probe used
in Southern blot analysis was a short fragment contained in exon 4. Targeted
ESCs were microinjected into C57BL/6 blastocysts, which were used to
generate chimeras. Male chimeras were mated to C57BL/6 female mice to
obtain F1 heterozygous offspring. The neomycin selection cassette was
deleted by crossing targeted heterozygous F1 with FLP deleter mice (The
Jackson Laboratory, strain 003946). Genotypes were verified by PCR and
Southern blot. The PCR primers used in genotyping were as follows: primer A,
50-GGGTCCCCTAGGAAATTCAA-30; primer B, 50-ATGATGCAGATGTTCTCT
CAGGGTG-30; and primer C, 50-ACAGGGGACTCACCC TACAAGG-30.
All mice were backcrossed to C57BL/6 for at least ten generations. Prm-cre
transgenic mice were purchased from Taconic. This study was reviewed and
approved by the institutional animal care and use committee of the National
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Preparation of Human Umbilical Cord Blood Cells
Human umbilical cord blood was collected as follows. After delivery, the cord
was clamped and cord blood was collected in a closed system from the
umbilical vein using a heparin-coated syringe. Donors were informedwith con-
sent guidelines provided by the institutional review board of Seoul National
University Hospital (IRB number: H-1210-032-430). After collection, mono-
nuclear cells were obtained using Ficoll-Paque Plus (GE Healthcare Life
Sciences) as previously described with slight modifications (Hur et al., 2004).
Isolated cells were maintained in ‘‘proliferation conditions’’ (StemSpan
H3000, STEMCELL Technologies) media with a cocktail of growth-stimulating
cytokines comprising FLT3L, SCF, IL3, and TPO (all from Peprotech).
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